FDA Guidance 2026: New August Updates Could Change How Sponsors Plan Generics, Biosimilars and CMC Programs
FDA’s August 2026 guidances update therapeutic equivalence, ANDA vs 505(b)(2), container closure systems and drug-development expectations.
Category: Pharma Compliance
Canada Wants Data on 200 Chemicals. The Hard Part May Be Finding It Across Your Supply Chain
Canada launches mandatory CEPA section 71 reporting for 200 priority substances, with Phase 1 responses due March 3, 2027.
An FDA Approval Does Not Automatically Mean Two Drug Products Are Interchangeable
FDA finalizes guidance explaining therapeutic-equivalence evaluations and Orange Book TE codes for multisource prescription drugs.
FDA finalizes type VII veterinary master file guidance
FDA’s Center for Veterinary Medicine finalized guidance in August 2026 explaining the use of Type VII Veterinary Master Files for research, development and certain risk reviews involving advanced veterinary technologies. The guidance is especially relevant to: The value is not simply a new file type. The important point is when…
One Manufacturing Change, Ten Countries, Ten Reviews? EMA Is Testing Another Way
EMA published new practical guidance on August 13, 2026 explaining how pharmaceutical companies can participate in pilots where national authorities rely fully or partially on EMA’s assessment of post-authorisation changes. The potential prize is substantial: fewer duplicated technical reviews and faster global implementation of approved changes. But reliance does not…
EMA’s Latest IDMP/PMS Update Is Really a Data-Governance Issue
EMA updated several Product Management Service/ISO IDMP implementation documents on August 12, including Chapter 3 covering the electronic submission and maintenance of medicinal-product information. For marketing authorization holders, this is less a “new regulation” story than a regulatory-data-governance story. The updated Chapter 3 is Version 3.7. EMA says this version…
How To Operationalize AI-Enabled eTMF Systems Under the EU AI Act
How to operationalize AI-enabled eTMF systems under EU AI Act: Steps for risk management, conformity assessments, human oversight, and GCP compliance to avoid €35M fines.
Hawaii FDA Ruling on Abortion Pill Sparks Big Pharma and Investor Jitters
Understand how the Hawaii FDA ruling on mifepristone reshapes abortion pill regulation, REMS compliance, telehealth access, and investor risk exposure.
Life Sciences Compliance News Analysis – October 3, 2025
Stay updated on the biggest compliance stories shaping pharma, healthcare, hospitals, and life sciences. From FDA warning letters to EMA inspections, HIPAA risks, clinical trial oversight, and global regulatory shifts—this digest covers the headlines compliance officers and executives can’t afford to miss.